Tatva Chintan Pharma Chem peers

Companies like Tatva Chintan Pharma Chemlatest year

Market cap and P/E at the last close; sales growth is the latest quarter on the same quarter a year before; ROE for the latest financial year.

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

TATVA₹1,614.80

Tatva Chintan Pharma Chem Limited

· Chemicals
₹ CrorePeersVISHNUJUBLCPLKIRIINDUSFOSECOINDCHEMPLASTSDDEVPLSTIKGUJALKALIYASHOMcap ₹3,777 Cr
Comp Set
In ₹ Crore except Per Share
Latest Annual
TATVA
FY26
VISHNU
FY26
JUBLCPL
FY26
KIRIINDUS
FY26
Peer
Average
Valuation — at last close
P/E89.81×27.33×22.91×◆ 0.55×16.93× +430%
P/B4.83×3.64×6.39×◆ 0.49×3.50× +38%
EV/EBITDA41.75×17.13×15.10×◆ 4.21×12.15× +244%
Market Cap₹3,777 Cr₹3,890 Cr₹2,938 Cr₹3,131 Cr₹3,320 Cr +14%
Growth
Revenue CAGR 3Y◆ 6.09%4.99%—-3.87%0.56% +987%
Revenue CAGR 5Y—◆ 18.85%—-8.45%5.20%
Net Income CAGR 3Y-2.58%1.37%—◆ 273.73%137.55% -102%
Revenue YoY (latest Q)◆ 75.94%24.93%18.38%54.54%32.62% +133%
Net Income YoY (latest Q)116.31%23.02%4.49%◆ 2768.13%931.88% -88%
Profitability
EBITDA Margin◆ 18.42%15.68%10.36%-26.31%-0.09% +20567%
Net Income Margin8.31%8.84%6.76%◆ 663.01%226.20% -96%
Return on Common Equity5.53%14.26%32.56%◆ 114.97%53.93% -90%
Return on Capital Employed7.36%16.33%◆ 40.33%-4.88%17.26% -57%
Return on Assets4.57%7.65%15.31%◆ 94.64%39.20% -88%
Credit & Quality
Total Debt/Equity0.15×0.49×0.06×◆ 0.01×0.19× -20%
Interest Coverage19.75×5.50×◆ 27.08×-1.37×10.40× +90%
Scale — latest FY
Revenue / Total Income₹506 Cr₹1,610 Cr₹1,891 Cr₹840 Cr₹1,447 Cr -65%
Net Income₹42.1 Cr₹142 Cr₹128 Cr₹5,567 Cr₹1,946 Cr -98%
Total Assets₹1,004 Cr₹2,088 Cr₹935 Cr₹7,039 Cr₹3,354 Cr -70%
EPS₹17.98₹21.14₹84.64₹941.32₹349.03 -95%
Book Value per Share₹334.2₹158.83₹303.56₹1,072.32₹511.57 -35%
◆ best value in the comp set per metric · Δ = subject vs average of the other companies.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.